Cedra names two new directors

They join business development in generics and automation for the bioanalytical division

Cedra Corporation, a division of Worldwide Clinical Trials and provider of Phase I-IIb clinical research and bioanalytical services, has appointed John Pottier as senior director of business development in generics and Thomas Lloyd as director of automation for the Bioanalytical Group.

Pottier has more than 17 years within the sales and marketing sector of the contract research organisation (CRO) market.

Prior to joining Cedra, Pottier held positions with Novum Pharmaceutical Research Services and PRACS Institute/Cetero Research relating to business development.

Lloyd has more than 22 years of experience in developing and automating analytical and bioanalytical processes. His specific expertise is in automation systems and analytical instrument development, bioanalytical chemistry, in vitro DMPK studies, software programming and application, statistics, chemometrics and GLP requirements.

Prior to joining Cedra, Lloyd led the automation group at Pfizer, previously known as Wyeth Research. He has held previous positions at DuPont Merck Pharmaceutical Company and Glaxo.

You may also like

Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Subscribe now